# Vedolizumab

## Entyvio inj 300mg

##### 臨採

| TAH Drug Code      | [IENT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IENT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Crohn disease or ulcerative colitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | IVD, ulcerative colitis, Crohn's disease 300 mg at week 0, 2 and 6, followed by every 8 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity reaction, severe or serious, to vedolizumab or any of its excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Gastrointestinal: Nausea (9% ) Musculoskeletal: Arthralgia (12% ) Neurologic: Headache (12% ) Respiratory: Nasopharyngitis (13% ), Upper respiratory infection (7% ) Other: Fatigue (6% ), Fever (9% ) Serious Hepatic: Aminotransferase abnormal, Increased (less than 2% ), Hepatitis, Serum bilirubin raised Immunologic: Anaphylaxis (0.07% ), Hypersensitivity reaction, Infusion reaction (4% ) Neurologic: Progressive multifocal leukoencephalopathy Respiratory: Tuberculosis Other: Cancer (0.4% ), Infectious disease, Sepsis (0.03% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Entyvio inj 108mg

##### 臨採

| TAH Drug Code      | [IENTH](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IENTH)   |
|:-------------------|:-------------------------------------------------------------------------|
| Indications        | No Data                                                                  |
| Dosing             | No Data                                                                  |
| Hepatic Impairment | No Data                                                                  |
| Renal Impairment   | No Data                                                                  |
| Contraindications  | No Data                                                                  |
| Adverse Effects    | No Data                                                                  |
| Pregnancy          | No Data                                                                  |
| Lactation          | No Data                                                                  |

